Business Description
Dabomb Protein Biotech Corp
ISIN : TW0006578008
Compare
Compare
Traded in other countries / regions
6578.Taiwan IPO Date
2016-07-20Description
Dabomb Protein Biotech Corp is a company specializing in antibiotic alternatives, and use postbiotics to boost immune strength and excel in innovative fermentation for improved plant protein utility. Their portfolio of products which include DBT-100 LS and DBT-100 HT , Liqui-TIDE bandage and LACTOTIDES HEALTH A+.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.03 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.44 | |||||
| Debt-to-EBITDA | -16.08 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.84 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.7 | |||||
| 3-Year FCF Growth Rate | -16 | |||||
| 3-Year Book Growth Rate | -8.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.96 | |||||
| 9-Day RSI | 59.64 | |||||
| 14-Day RSI | 61.03 | |||||
| 6-1 Month Momentum % | 39.23 | |||||
| 12-1 Month Momentum % | 24.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.18 | |||||
| Quick Ratio | 2.13 | |||||
| Cash Ratio | 1.2 | |||||
| Days Inventory | 35.76 | |||||
| Days Sales Outstanding | 40.93 | |||||
| Days Payable | 15.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.38 | |||||
| 3-Year Dividend Growth Rate | 14.2 | |||||
| Forward Dividend Yield % | 2.38 | |||||
| 5-Year Yield-on-Cost % | 2.38 | |||||
| 3-Year Average Share Buyback Ratio | -20.9 | |||||
| Shareholder Yield % | -12.03 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 12.08 | |||||
| Operating Margin % | -7.79 | |||||
| Net Margin % | -14.83 | |||||
| FCF Margin % | -3.22 | |||||
| ROE % | -6.7 | |||||
| ROA % | -4.08 | |||||
| ROIC % | -2.89 | |||||
| ROC (Joel Greenblatt) % | -5.23 | |||||
| ROCE % | -4.23 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 46.27 | |||||
| PS Ratio | 3.8 | |||||
| PB Ratio | 1.76 | |||||
| Price-to-Tangible-Book | 1.75 | |||||
| Price-to-Operating-Cash-Flow | 760.81 | |||||
| EV-to-EBIT | -36.82 | |||||
| EV-to-EBITDA | -67.58 | |||||
| EV-to-Revenue | 4.57 | |||||
| EV-to-FCF | -141.28 | |||||
| Price-to-Net-Current-Asset-Value | 5.02 | |||||
| Earnings Yield (Greenblatt) % | -2.72 | |||||
| FCF Yield % | -0.7 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers